Graduate Theses, Dissertations, and Problem Reports
2014

IL-15 Signaling in Skeletal Muscle: Implications in Modulation of
PGC-1alpha and Mitochondrial Biogenesis
Grant C. O'Connell

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
O'Connell, Grant C., "IL-15 Signaling in Skeletal Muscle: Implications in Modulation of PGC-1alpha and
Mitochondrial Biogenesis" (2014). Graduate Theses, Dissertations, and Problem Reports. 6337.
https://researchrepository.wvu.edu/etd/6337

This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

IL-15 Signaling in Skeletal Muscle: Implications
in Modulation of PGC-1α and Mitochondrial
Biogenesis

Grant C. O’Connell

Thesis submitted
to the School of Medicine
at West Virginia University
in partial fulfillment of the requirements for the degree of
Master of Science in
Exercise Physiology

Emidio E. Pistilli, Ph.D., Chair
Stephen E. Alway, Ph.D.
John M. Hollander, Ph.D.
Division of Exercise Physiology

Morgantown, West Virginia
2014

Keywords: Interleukin-15, Interleukin-15 Receptor Alpha, Skeletal Muscle,
Mitochondria, PGC-1a, PPARd
Copyright 2014 Grant C. O’Connell

ABSTRACT
IL-15 Signaling in Skeletal Muscle: Implications
in Modulation of PGC-1α and Mitochondrial
Biogenesis
Grant C. O’Connell
Altering interleukin-15 (IL-15) signaling through ablation of interleukin receptor alpha (IL15Rα) in the IL-15Rα global KO mouse has been shown to result in an oxidative shift in skeletal
muscle characterized by enhanced fatigue resistance and increases in mitochondrial density.
However, the mechanism of this phenomenon is unclear, as IL-15 signaling in skeletal muscle has
been virtually unexplored. It has been previously suggested that loss of IL-15Rα in the global KO
mouse directly results in an increase in muscle IL-15 secretion, and this increase in secreted IL-15
acts on skeletal muscle in an autocrine fashion, directly stimulating pro-oxidative remodeling.
Thus, the purpose of this study was to examine the effects of muscle IL-15Rα loss on the ability of
muscle to secrete and respond to IL-15, and also to determine whether IL-15 has the ability to act
directly on skeletal muscle to induce pro-oxidative changes. These aims were addressed through
the generation of C2C12 myogenic cell lines lacking IL-15Rα, as well as a through the
development of a novel muscle-specific IL-15Rα KO mouse. Myogenic cell cultures lacking IL15Rα failed to exhibit the capacity to respond to exogenously provided IL-15. Furthermore, IL15Rα-null cultures displayed a depressed ability to secrete IL-15, even in the presence of proinflammatory stress. In support of this observation, mice lacking IL-15Rα conditionally in skeletal
muscle exhibited no changes in circulating IL-15. However, acute treatment of wild type
myogenic cultures with IL-15 resulted in induction of the pro-oxidative genes PGC-1α and
PPARδ. These results provide evidence that IL-15 has the capacity to act directly on skeletal
muscle in a pro-oxidative manner, and that loss of IL-15Rα ablates the ability of skeletal muscle to
secrete and respond to IL-15. Collectively, these results suggest that the muscle changes observed
in the IL-15Rα KO mouse are driven by increased muscle response to IL-15, but that the ability to
secrete and respond to IL-15 is enhanced in the global IL-15Rα KO mouse due to a confound such
as immunodeficiency.
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Chapter 1.

Introduction:
Proper mitochondrial function is essential in maintaining cellular homeostasis. The
mitochondrial network is the primary regulator of cellular metabolism and energy status;
disruptions in cellular ATP supply by way of mitochondrial dysfunction severely impairs cell
function and as a result plays a central role in the pathogenesis of a wide array of severe
neurological, metabolic, and myogenic disorders. Mitochondrial dysfunction, which is
characterized by impaired mitochondrial oxidative capacity, has been implicated as a key
component in the pathologies of Alzheimer’s, Huntington’s, Parkinson’s, ALS, diabetes, obesity,
aging and cancer cachexia.1–6 Increasing mitochondrial mass by way of mitochondrial
biogenesis in conditions of mitochondrial dysfunction has been shown to improve total cellular
oxidative capacity and prevent bioenergetic crisis, thus rescuing cellular function, reducing
symptom severity, and improving quality of life.7–14 As a result, there has been a recent push for
the development of therapies which stimulate mitochondrial biogenesis by targeting peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a transcriptional coactivator which is known to be one the key regulators of mitochondrial replication. Previously
published and preliminary data produced by our laboratory using a transgenic mouse model has
provided evidence that altering signaling of the cytokine interleukin 15 (IL-15) by global
knockout of one of its key regulatory proteins, interleukin 15 receptor alpha (IL-15Rα), results in
potent activation of PGC-1α transcription, significant increases in mitochondrial mass, and
improved oxidative capacity in the skeletal muscle of mice.15,16 Because it is evident that
modulating IL-15 and IL-15Rα can elicit dramatic positive mitochondrial changes, determining
the specific nature of the changes and the signaling mechanisms responsible provides potential
for the development of therapies targeting IL-15 in disease states involving mitochondrial
dysfunction. Unfortunately, it is unclear how loss of IL-15Rα affects IL-15 signaling in skeletal
1

muscle, as IL-15 signaling in muscle is relatively uncharacterized. It has been previously
suggested that loss of IL-15Rα in the global KO mouse directly results in an enhanced ability of
skeletal muscle to secrete IL-15, and that this increase in secreted IL-15 acts on muscle in an
autocrine fashion, resulting in the pro-oxidative changes which have been characterized.16,17
However, this mechanistic explanation for the exercise and muscle phenotypes in the global IL15Rα KO mouse is complicated by the fact that IL-15Rα is ubiquitously absent, making it difficult
to determine whether the effects of IL-15Rα loss in non-muscle tissues contribute to the
changes observed in skeletal muscle, or whether these changes are a direct result of IL-15Rα
loss in muscle tissue alone. In an additional complication, this mechanistic explanation for the
changes observed in the IL-15Rα global KO mouse suggests that the action of IL-15 in muscle
differs in some aspects from what is observed in the immune system, in which IL-15Rα is
essential for the ability of cells to secrete and respond to IL-15.18–22
Thus, based on the lack of current knowledge regarding the exact function and
mechanism of IL-15 signaling in skeletal muscle, as well as the promising mitochondrial
changes observed with loss of IL-15Rα in the global KO mouse, the purpose of this project was
to further investigate the previously proposed mechanism for the pro-oxidative muscle changes
which have been observed with IL-15Rα loss. Therefore, this project had three specific aims:
Aim 1:
Determine the effects of muscle-specific IL-15Rα loss on skeletal muscle IL-15 secretion.
Hypothesis 1:
Loss of IL-15Rα specifically in skeletal muscle increases IL-15 secretion.
Aim 2:
Determine how loss of IL-15Rα impacts the ability of skeletal muscle to respond to IL-15.
Hypothesis 2:
Loss of IL-15Rα negatively impacts the ability of skeletal muscle to respond to IL-15, but IL-15
signaling can persist without IL-15Rα in the presence of sufficiently elevated levels of IL-15.
Aim 3:
Determine whether IL-15 acts directly on skeletal muscle to induce pro-oxidative changes.
Hypothesis 3:
IL-15 has the capacity to act directly on skeletal muscle in a pro-oxidative manner.
2

Aim one was addressed in vitro via the generation of C2C12 myoblasts lacking IL-15Rα,
as well as in-vivo using a conditional muscle specific IL-15Rα mouse model. It was expected
that loss of IL-15Rα in both contexts would result in measureable increases in IL-15 secretion.
IL-15Rα-null myoblasts were also used to address aim two; it was expected that loss of IL-15Rα
would negatively impact the ability of myogenic cultures to respond to exogenously provided IL15, but that IL-15 signaling would be possible at elevated concentrations. The third aim was
addressed through the treatment of wild type skeletal muscle cultures with recombinant IL-15. It
was expected that IL-15 treatment would result in a similar increase in mitochondrial mass as
observed in the IL-15Rα global KO mouse.

3

Chapter 2.

Background:
2.1
Functional mitochondria are essential in maintaining cellular homeostasis:
Adenosine triphosphate (ATP) is nucleoside triphosphate composed of a single
adenosine molecule bound to three phosphate groups. In biological systems, hydrolysis of the
anhydride bond linking the γ and β phosphate to form adenosine diphosphate and free
phosphate results in the release of free energy. This free energy can be utilized by the cell to do
work. A majority of the most critical cellular processes including active membrane transport,
intracellular signal transduction, and protein synthesis require ATP as a substrate. Due to the
involvement of ATP in such a vast number of cellular processes, ATP is constantly being
hydrolyzed, and thus needs to be constantly replenished in order for these cellular processes to
continue without interruption.
In most mammalian cell types, the majority of ATP is synthesized by subcellular
organelles known as mitochondria via a process known as oxidative phosphorylation
(OXPHOS). Mammalian cells contain a vast and fluid mitochondrial network. Mitochondria are
characterized by a double membrane structure and are unique in respect to other organelles in
that they contain a circular genome distinct from the nuclear genome. Mitochondrial DNA
(mtDNA) contains 13 genes which encode for mitochondrial polypeptides which constitute
critical subunits in the OXPHOS machinery, as well as 24 genes which produces the transfer
RNAs and ribosomal RNAs necessary for mitochondrial protein assembly. While the
mitochondria employ a self-contained genome, many of the genes which encode protein
essential for mitochondrial assembly and function are located on the nuclear genome. The
nuclear genome encodes mitochondrial transcription factor A (TFAM) and mitochondrial DNA
polymerase (POLG), which are proteins essential for mitochondrial DNA transcription and
replication. The nuclear genome also codes for the remaining OXPHOS proteins, as well
numerous structural, enzymatic, and transport proteins.23–25 Many of these nuclear genes are
under the control of the nuclear respiratory factor (NRF), estrogen-related receptor (ERR), and
peroxisome proliferator-activated receptor (PPAR) families of transcription factors.26 The rate of
mitochondrial turnover is high; radioactive isotope pulse chase experiments have shown that
mitochondrial half-life may be as short as 1.3 days in highly metabolically active tissues such as
4

the liver,

and mitochondria are constantly produced and degraded through processes

respectively known as mitochondrial fission and mitophagy.27
The double membrane mitochondrial structure is essential in terms of role mitochondria
play in energy production. Mitochondria are composed of two phospholipid bilayer membranes
referred to as the inner mitochondrial and outer mitochondrial membranes, the second of which
displaying low ionic permeability. The space between the inner and outer membrane is known
as the inter-membrane space and the area within the inner-membrane is known as the
mitochondrial matrix. The protein machinery most directly involved in ATP synthesis, the
respiratory chain proteins, are located on the inner-membrane. Invaginations of the innermembrane known as cristae provide expanded surface area and increase the capacity to
produce ATP. During oxidative phosphorylation, the respiratory chain proteins use hydrogenderived electrons generated through the oxidation of organic acids to reduce oxygen to form
water and in the process generate ATP. Oxidation of pyruvate and fatty acids through various
metabolic processes such as the beta oxidation and the citric acid cycle (TCA) produces
hydrogen bound to the electron carriers flavin adenine dinucleotide (FAD) and nicotinamide
adenine dinucleotide (NAD). Electrons derived from FADH2 and NADH are then passed through
the the respiratory chain proteins of the mitochondrial inner-membrane via a series of oxidation
and reduction reactions, and in the process move matrix protons across the membrane into the
inter-membrane space. The first respiratory chain protein, a trans-inner-membrane protein
known as NADH dehydrogenase (Complex 1), binds and oxidizes matrix NADH. The electrons
derived from NADH oxidation are used by NADH dehydrogenase to reduce coenzyme Q (CoQ),
a lipid soluble quinone found within the lipid bilayer of the inner-membrane. This transfer of
electrons from NADH to CoQ through complex 1 results in the movement of protons from the
matrix

to

the

inter-membrane

space.

The

trans-inner-membrane

protein

succinate

dehydrogenase (Complex 2) oxidizes succinate to fumarate during the TCA cycle which
generates FADH2. FADH2 is than oxidized by complex two and the transferred electrons are
used to reduce CoQ. CoQ reduced by complexes 1 and 2 are oxidized by another trans-innermembrane protein known as cytochrome reductase (Complex 3). Electrons gained by complex
3 via CoQ oxidation are then used to reduce cytochrome C, a heme protein located in the intermembrane space. Movement of electrons from CoQ to cytochrome C through complex 3 also
results in the movement of matrix protons to the inter-membrane space. The transmembrane
protein cytochrome C oxidase (Complex 4) then transfers electrons from reduced to cytochrome
C back to the matrix where they can be used to reduce oxygen, forming water. This final
5

electron transfer through complex 4 once again results in proton movement. The cumulative
result of the activity of the respiratory chain proteins is a high concentration of protons in the
inter-membrane space as opposed to the matrix. ATP synthase is a protein integral to the innermembrane which forms a proton pore. Protons move down their electrochemical gradient
through ATP synthase and in the process drive the formation of ATP from ADP and free
phosphate.28 Interruption of a single step of this complex process can result in dramatically
reduced ATP production, thus disrupting cellular energy supply and the ability of the cell to carry
out homeostatic processes.
2.2
Mitochondrial dysfunction:
Mitochondrial dysfunction is a general term which can be used to describe situations
during which the ability of the mitochondria to produce ATP by way of oxidative phosphorylation
is impaired. The bio-energetic crisis that occurs as a result of mitochondrial dysfunction severely
impairs cellular function and through several indirect pathways can result in apoptosis.
Interruptions in mitochondrial ATP supply severely limit the ability of the cell to carry out many
critical ATP-dependent processes. As a result, during states of mitochondrial dysfunction, there
is typically a substantial compensatory up-regulation of ATP production by way of anaerobic
pathways, which can result in cellular acidification. Cellular acidosis can interfere with many pHdependent biochemical reactions and further hinder cellular function.29 Interruptions in the
function of the respiratory chain proteins not only reduces cellular ATP supply and impairs
cellular homeostatic function, but in many cases results in the production of mitochondrial
reactive oxygen species (ROS), which in turn can trigger mitochondrial-mediated apoptotic
pathways as well as place the cell in a state of oxidative stress.30,31
During conditions which respiratory chain electron transport is inhibited, there is an
increase in mitochondrial matrix ratio of NADH to NAD+. Increases in matrix NADH can lead to
electron saturation of the flavin mononuclotide (FMN) group of complex 1. When FMN becomes
electron saturated, it readily reacts with oxygen to produce superoxide.32 Impaired electron
transport ability can also lead to the electron saturation of the CoQ pool. If the ratio of reduced
CoQ to oxidized CoQ becomes too high, a phenomenon known as reverse electron transport
(RET) can occur. During RET, electrons from reduced CoQ are transferred back to the CoQ
binding domain of Complex 1. This atypical flow of electrons also produces superoxide,
potentially once again through FMN saturation.33 While these are only two examples by which
6

electron transport interruption produces ROS, many other mechanisms exist, many directly
related to electron saturation of the NAD or CoQ pools.30,31 Constitutive production of
mitochondrial ROS promotes the initiation of pro-apoptotic events such as mitochondrial
permeability transition pore opening and cytochrome C release.34 In addition to the initiation of
apoptotic signaling cascades, ROS produced in states of impaired respiratory chain function
damage the respiratory chain proteins themselves, further exacerbating the situation, resulting
in further ROS generation. Excessive ROS also damages mtDNA and can lead to the
production of defective mitochondrial proteins.35 Due to the host of problems induced by deficits
in the ability to produce energy through oxidative pathways, it is not surprising that mitochondrial
dysfunction has been identified as key component in the pathologies of several of the most
common and severe human conditions ranging from metabolic disorders such as diabetes to
neurodegenerative diseases such as Hunginton’s, Parkinson’s, Alzheimer’s, and dementia.1,5,29
2.3
Mitochondrial biogenesis and PGC-1α: Implications in the treatment of mitochondrial
dysfunction:
Increasing mitochondrial mass in conditions in which there is a respiratory deficit may
hold great promise in preventing bioenergetics crisis and rescuing cellular function. Increasing
mitochondrial mass by way of mitochondrial biogenesis in has been shown to raise residual
oxidative capacity in affected tissues, limit functional impairment, reduce symptom severity, and
improve quality of life. Inducing mitochondrial biogenesis has the potential to improve clinical
outcome in a wide array of disorders through a variety of mechanisms, primarily through
increasing cellular energy supply and decreasing ROS formation.7–13 In many conditions
involving mitochondrial dysfunction, impaired ability of the mitochondria to produce ATP is
thought to play a major role in disease pathology through the homeostatic stress a diminished
energy supply can place on cells in the affected tissues. In several of these conditions, defects
or deficiencies in the respiratory chain proteins by way of gene mutations results in decreased
ATP production. In a condition where there is a 50% decrease in ATP production per unit of
mitochondrial mass, doubling mitochondrial mass holds the potential to return the total amount
of ATP produced by the entire mitochondrial population back to healthy levels. While this
strategy does not address the underlying cause of the respiratory deficit itself, increasing
cellular ATP supply allows more energy for cellular homeostatic function and could improve
overall tissue functionality.14 This is especially true in conditions caused by heteroplasmic
7

mtDNA mutations. The mtDNA mutations that are accrued with aging are a good example.
Throughout the life span, oxidative stress and uncorrected replication errors result in mtDNA
mutations on a copy by copy basis, not as a populational phenomenon.3 Copies of a single
mutation will expand through replication but usually will only be carried by a portion of the entire
pool of mtDNA. In heteroplasmic conditions, the mutation or mutations most responsible for
functional detriments may be only carried by a portion of mitochondrial population while the
remaining populating may carry corresponding wild type alleles. Stimulating mitochondrial
biogenesis in these cases will result in expansion of the functional wild-type population which in
turn could greatly enhance cellular OXPHOS capacity.14
Another mechanism by which stimulating mitochondrial biogenesis could be beneficial in
conditions of mitochondrial dysfunction is through limiting mitochondrial ROS generation. The
ROS generated as a result of mitochondrial dysfunction are thought to play an import role in the
progression of several neurodegenerative diseases, especially Alzheimer’s, as prolonged
oxidative stress can result in impaired cellular function and the initiation of apoptotic signaling
cascades.1,36 Saturation of the respiratory complexes with electrons during states of low
respiratory capacity and high energy demand results in the generation of ROS which in turn can
cause damages to the respiratory proteins themselves, further decreasing their functionality,
resulting in even greater propensity for ROS production30,31. Increasing the turnover of ROS
damaged mitochondrial proteins through mitochondrial biogenesis could potentially limit this
vicious cycle and depress cellular oxidative stress.11
PGC-1α is a transcriptional co-activator which has been shown to induce the expression
of genes known to be essential for mitochondrial biogenesis, modulation of mitochondrial
function, and ROS detoxification.26,37 PGC-1α has the ability to potently induce increases in
mitochondrial mass,38 and as a result, is being increasing sighted as a therapeutic target in
mitochondrial diseases and conditions which involve mitochondrial dysfunction.14,39
In terms of activity, PGC-1α is regulated at both the translational and post-translational
level. PGC-1α transcription is induced through various stimuli linked to cellular metabolism and
energy status. PPARs are a family of ligand-induced transcription factors activated by various
eicosanoids and fatty acids and were some of the first transcription factors shown to induce
PGC-1α gene expression.40 PGC-1α expression under the CREB and MEF2 transcriptions
factors is also initiated by AMPK,41,42 one of the master sensors of cellular energy status, by
calcineurin and various CAMKs,43 which are sensitive to cellular calcium load, as well as by
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cAMP dependent pathways,44 which are sensitive to cellular glucose metabolism. PGC-1α
expression is also induced by increases in ROS, oxygen, and nitric oxide through a variety of
mechanisms.37 Expectedly, exercise strongly stimulates PGC-1α gene expression and a myriad
of the adaptations that occur with exercise are believed to be a result of PGC-1α activity.45
Some of the same factors that are responsible for initiating PGC-1α transcription are
also responsible for its post-translational activation. PGC-1α has a relatively limited half-life;
phosphorylation of a series of tyrosine and serine residues by substrates such as AMPK and
p38 MAPK have been shown to significantly stabilize the protein.46,47 One of the most
documented post-translational modifications shown to be essential for PGC-1α activity is
deacetylation of several acetylation sites between amino acids 200 and 400 by Sirt1, a class 3
histone/protein deacetylase whose activity requires NAD as a cofactor, again strongly linking
PGC-1α activity to cellular energy status.48 Once post-translationally active, PGC-1α can bind
and enhance the activity of several transcription factors that regulate genes associated with
mitochondrial biogenesis and function. Cofactors activated by PGC-1α include multiple
members of the PPAR family, NRF1, NRF2, as well as EER family members.26 In addition to the
role PGC-1α has been shown to play in mitochondrial biogenesis, it is believed PGC-1α is
involved in regulating several genes involved in ROS defense. PGC-1α activity has been
strongly associated with superoxide dismutase (SOD) and glutathione peroxidase expression.49
In many contexts, PGC-1α can promote uncoupling protein expression which can dissipate the
mitochondrial proton gradient, resulting in lesser potential for ROS formation.38 Consistent with
this role, PGC-1α KO mice display elevated levels of ROS in a multitude of highly metabolically
active tissues such as brain and muscle.50 This additional role as a promoter of antioxidant
defense makes PGC-1α an intriguing therapeutic target in conditions where the oxidative stress
aspect of mitochondrial dysfunction plays a prominent role.
2.4
IL-15: A potential novel target in mitochondrial dysfunction:
IL-15 is a recently discovered four-helix bundle cytokine which has been heavily studied
regarding its role in regulating immune homeostasis. IL-15 has been characterized as a
lymphocyte differentiation factor as well as promoter of natural killer cell maturation.51 IL-15 is
also believed to be a potent inflammatory chemokine and has been shown to be essential in
directing immune responses in inflammatory conditions such as arthritis52,53 and celiac
disease.54 Over-activity of IL-15 can induce chronic inflammatory states and autoimmune
9

conditions through the promotion of t-cell auto-reactivity and as a result, its activity is tightly
regulated through a wide variety of pre and post-translational mechanisms.51 One of the primary
regulators of IL-15 activity is a non-signaling receptor known as IL-15Rα. IL-15Rα is not a
traditional receptor in that it does not have the capacity for signal transduction, and is more aptly
though of simply as an IL-15 binding protein.55,56 Despite the fact that IL-15 and IL-15Rα are
expressed in virtually every tissue,56,57 IL-15 function in non-immune tissues is widely unknown.
Data collected by our laboratory using a transgenic mouse model lacking IL-15Rα
suggests that IL-15 is a potential regulator of mitochondrial biogenesis in skeletal muscle.
Electron micrographs have provided evidence that muscle tissue from the transgenic line
contains up to 40% more mitochondrial mass than muscle extracted from wild type mice when
analyzed by point counting.15 Supporting quantitative PCR analysis shows an increase in
mitochondrial DNA content15 and western blot has shown increased protein levels of
cytochrome oxidase.16 Mitochondria-rich muscle from the knock out model is functional and
displays increased oxidative capacity when analyzed using ex-vivo functional tests; fatigue
profiling has revealed that extensor digitorum longus muscle from the KO line is significantly
more fatigue resistant compared to controls.16 Furthermore, significant increases in PPARδ and
PGC-1α mRNA in transgenic muscle suggests that the higher mitochondrial density and
increased oxidative capacity observed in the KO line is a result of mitochondrial biogenesis
stimulated by increased PGC1α activity.16 The changes seen in muscle as a result of IL-15Rα
loss make IL-15 and IL-15Rα potential targets for therapies in conditions of mitochondrial
dysfunction. However, the mechanisms by which loss of IL-15Rα results in mitochondrial
changes have not yet been elucidated, as IL-15 signaling mechanisms in skeletal muscle have
been virtually un-explored.
Skeletal muscle constitutes the largest IL-15 mRNA pool in the body , and loss of IL15Rα in the global KO mouse has been shown to result in increases in muscle IL-15 transcript.16
This observation, combined with observations of dramatic increases in circulating IL-15,58 led to
the suggestion that IL-15 secretion from skeletal muscle is increased as a direct result of IL15Rα loss.16,17 Furthermore, based on studies reporting similar oxidative muscle changes and
exercise phenotypes in animals with systemically elevated IL-15,59,60 it was suggested that this
increase in circulating IL-15 acts directly on skeletal muscle, resulting in the pro-oxidative
changes originally observed in the global IL-15Rα KO mouse (Figure 1).17 However, this
mechanistic explanation for the muscle phenotype observed in the global IL-15Rα KO mouse
would suggest that IL-15 signaling in skeletal muscle differs in some aspects from what is
10

Figure 1. Currently proposed
mechanism of pro-oxidative
muscle remodeling with loss of
IL-15Rα.
(1) Loss of IL-15Rα as an inhibitory
transcriptional cofactor in skeletal
muscle results in an increase in IL15 transcription and secretion. (2)
Increases in secreted IL-15 act
directly on skeletal muscle in an
autocrine fashion to increase IL-15
signal transduction. (3) Increases
in IL-15 signaling directly induce
pro-oxidative gene expression and
promote oxidative remodeling.

observed in the immune system, where IL-15Rα is essential for the ability of cells to secrete and
respond to IL-15.18–22,61
In immune cells, IL-15 activity is regulated in terms of transcription, secretion, and signal
transduction by several soluble and membrane bound isoforms of IL-15Rα which are generated
through alternative splicing.62
An intracellular isoform of IL-15Rα has been shown to play a potentially pivotal role in
regulating IL-15 at the transcriptional level. Intracellular IL-15Rα contains a nuclear translocation
domain and is commonly observed associated with the nuclear membrane in histochemical and
cytochemical analysis and has been detected in nuclear protein fractions.63 Evidence has been
shown that during states of high IL-15 production such as inflammation, intracellular IL-15-Rα
binds cytosolic IL-15, translocates to the nucleus, and limits further IL-15 transcription potentially
through function as an inhibitory transcriptional cofactor (Figure 2A).63 It is logical to believe that
loss of IL-15Rα in this context may account for the mechanism by which an increase in muscle
IL-15 mRNA is observed in the global knockout mouse. However, studies exploring the role that
IL-15Rα plays in regulating IL-15 secretion in the immune system would suggest that this
increase in IL-15 mRNA may not result in an increase in IL-15 release in the absence of IL15Rα.18,20,64
IL-15 contains an inefficient signal peptide and free IL-15 is not easily secreted from the
cell.

64

While secretion of free IL-15 does occur, it is released much more effectively using IL-

15Rα as a chaperone. Certain splice variants of IL-15Rα contain a highly effective signal
peptide which allows for easy secretion; association of a soluble isoform of IL-15Rα with IL-15
11

within the secretory pathway allows for the secretion of a soluble IL-15Rα /IL-15 complex which
is more efficiently released than IL-15 alone (Figure 2B).20 IL-15 can also internally dimerize
with a transmembrane domain-containing isoform of IL-15Rα and be presented at the plasma
membrane where it can signal as a cell surface marker.18 This role of IL-15Rα as a chaperone
to secretion in the immune system presents an obvious contradiction to the increases in
circulating IL-15 reported in the IL-15Rα KO mouse.
IL-15Rα not only regulates IL-15 activity at the transcriptional and secretory level, in the
immune system, IL-15Rα is also heavily involved in modulating IL-15 signal transduction. On
immune cells, IL-15 signals via a receptor complex composed of interleukin 2 receptor beta (IL2Rβ) and the common cytokine receptor gamma chain (γc) by way of classic receptor tyrosine
kinase mechanisms.57 Both IL-2Rβ and γc contain cytoplasmic domains capable of janus kinase
3 (JAK3) association. IL-15 binding results in ligand induced dimerization of IL-2Rβ and γc
allowing for JAK3 trans-phosphorylation, an event which promotes the phosphorylation of
several n-terminus tyrosine residues on both receptors. N-terminus tyrosine phosphorylation
allows for the recruitment and phosphorylation of cytoplasmic signal transducer and activator of
transcription (STAT) family members, most notably STAT5. These phosphorylated STATs
dissociate from the receptor complex, form various homo and heterodimers, and ultimately
initiate transcriptional changes.65 Presence of IL15-Rα in a variety of signaling scenarios greatly
enhances the ability of IL-15 to signal through IL-2Rβ and γc. Association of IL-15Rα with IL-15
results in a slight conformational change which enhances the ability of IL-15 to bind to the
signaling receptors; the soluble secreted IL-15Rα/IL-15 complex exhibits 150-fold greater affinity
for the IL-15 signaling receptors than free IL-15 alone (Figure 2C).66,67 A membrane-bound
isoform of IL-15Rα is often closely associated with the IL-15 signaling receptors at the plasma
membrane, forming a trimeric receptor complex. While IL-15Rα does not contain a cytoplasmic
domain and does not potentiate an intracellular signal, its presence in the trimeric complex
greatly increases the affinity of free IL-15 for the signaling receptors in a stepwise fashion. In the
trimeric receptor complex scenario, free IL-15 first binds membrane- bound IL-15Rα, binding
results in an IL-15 conformational change, and IL-15 then strongly associates with the signaling
receptors and signaling is initiated (Figure 2C).66 One of the most important and well
characterized immune signaling mechanisms in IL-15 biology is the process of transpresentation, a process in which IL-15Rα is essential. During trans-presentation, membranebound IL-15Rα presents IL-15 as a cell surface marker. This membrane tethered IL-15 can then
interact with and initiate signaling through the IL-15 signaling receptors located on adjacent and
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Figure 2. Regulatory actions of IL-15Rα within the immune system.
(A) During states of high IL-15 production such as inflammation, Intracellular IL-15Rα can bind
intracellular IL-15 in the cytoplasm and translocate to the nucleus where it can act to inhibit further
IL-15 transcription. (B) Intracellular IL-15Rα can bind IL-15 in the secretory pathway, forming a
heterodimer which is more efficiently secreted than the IL-15 free monomer. (C) The presence of IL15Rα in the IL-15/IL-15Rα heterodimer or as a membrane bound receptor greatly increases the
affinity of IL-15 for the signal transducing complex of IL-2Rβ and IL-2Rγ.
surrounding cells. Trans-presentation is the primary signaling mechanism by which IL-15
induces lymphocyte differentiation and NK-cell development.18,21,68 This action can be ablated
by the action of a metalloprotease known as tumor necrosis factor a converting enzyme (TACE).
TACE cleaves IL-15Rα, releasing the IL-15/IL-15Rα complex from the plasma membrane,
eliminating the potential for trans presentation.69 Due to the fact that IL-15Rα does not
potentiate an intracellular signal in any of these scenarios, it is believed that IL-15 signal
transduction can still occur in its absence.70 However, if IL-15Rα plays a similar regulatory role
in skeletal muscle as it does in the immune system, it is logical that an increase in IL-15 signal
transduction is unlikely in the muscle of the global IL-15Rα KO mouse as previously suggested,
even in the presence of increased circulating IL-15.
In addition to the paradoxes the previously proposed mechanism for the oxidative
changes observed in the IL-15Rα global KO mouse present to immune IL-15 signaling, it is
further complicated by the fact that IL-15Rα is ubiquitously absent in the model, making it
difficult to determine whether the effects of IL-15Rα loss in non-muscle tissues contribute to the
changes characterized in skeletal muscle, or whether these changes were a direct result of IL15Rα loss in muscle tissue. In the CNS, IL-15 and IL-15Rα have been shown to play an
essential role in regulating the turnover and synaptic reuptake of gamma-aminobutyric acid
(GABA), the most prevalent inhibitory neurotransmitter in the central nervous system.71 IL-15Rα
KO mice display significantly depressed GABA levels, a phenotype commonly seen in attention
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deficit and hyperactivity disorders.71 IL-15Rα KO mice display a hyperactive phenotype16,71,72
and it is possible that the increases in mitochondrial mass and changes in PGC-1α observed in
this model are simply a result of adaptations which are commonly seen with increases in
physical activity. IL-15 has also been shown to stimulate the release of free-fatty acids from
adipocytes and promote fat metabolism.73–75 IL-15Rα KO mice are leaner16 and display
respiratory exchange ratio (RER) values indicative of increased fat metabolism.58 Increased
exposure of the muscle to fatty acid substrates by way of IL-15-mediated adipocyte fatty acid
release could increase the activity of PPARs and PGC-1α, as they are sensitive to cellular fatty
acid load. Due to the general complexity of cytokine signaling, it is possible that alterations in IL15-mediated release of any number of factors from numerous cell types could be the cause of
the oxidative phenotype observed in the IL-15Rα KO mouse.
Thus, based on the lack of current knowledge regarding the exact function and
mechanism of IL-15 signaling in skeletal muscle, as well as the promising mitochondrial
changes observed with loss of IL-15Rα in the global KO mouse, the mechanism responsible for
the pro-oxidative muscle changes which have been observed with IL-15Rα loss warrant further
investigation.
2.5
Background summary, aims, and hypotheses:
Therapies which increase mitochondrial mass by way of PGC-1α activation have shown
great promise in offsetting the detrimental effects of mitochondrial dysfunction, a condition
implicated in the pathologies of some the most prevalent and severe human diseases and
disorders. Altering IL-15 signaling through ablation of IL-15Rα in the IL-15Rα global KO mouse
has been shown to potently stimulate mitochondrial biogenesis in skeletal muscle via PGC-1α,
implicating IL-15 and IL-15Rα as potential targets in conditions of mitochondrial dysfunction if
the mechanisms involved can be elucidated. However, IL-15 signaling in skeletal muscle
remains virtually unexplored. It has been previously suggested that loss of IL-15Rα in the global
KO mouse directly results in an increase in muscle IL-15 secretion, and this increase in
secreted IL-15 acts on skeletal muscle in an autocrine fashion, directly stimulating pro-oxidative
remodeling. However, this mechanistic explanation for the pro-oxidative changes observed in
the skeletal muscle of the IL-15Rα KO mouse is complicated by the fact that IL-15Rα is absent
in all tissues, making it difficult to determine whether the changes observed in muscle are a
direct result of IL-15Rα loss in the muscle alone, or if changes in non-muscle tissues play a
14

contributing role. In an additional complication, this mechanistic explanation would suggest that
IL-15 signaling in skeletal muscle differs in some aspects from what is observed in the immune
system, in which IL-15Rα is essential for the ability of cells to secrete and respond to IL-15.
Therefore, this project had three specific aims: first, to determine how loss of IL-15Rα in
skeletal muscle influences IL-15 secretion, second, to determine how loss of IL-15Rα impacts
the ability of skeletal muscle to respond to IL-15, and third, to determine whether IL-15 acts
directly on skeletal muscle to induce pro-oxidative changes. The first two of these aims were
addressed in vitro via the generation of C2C12 myoblasts lacking IL-15Rα, as well as in-vivo
using a conditional muscle specific IL-15Rα mouse model. It was hypothesized that loss of IL15Rα would result in an increase in IL-15 secretion. Furthermore, it was hypothesized that loss
of IL-15Rα would negatively impact the ability of skeletal muscle to respond to IL-15, but that IL15 signaling could persist without IL-15Rα in the presence of sufficiently elevated levels of IL15. The third aim was addressed through the treatment of skeletal muscle cultures with
recombinant IL-15. It was hypothesized that IL-15 treatment would result in a similar increase in
mitochondrial mass as observed in the IL-15Rα global KO mouse.
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Chapter 3.

Results:
3.1
Generation of stable IL-15Rα KO myoblasts:
In order to address the effects of IL-15Rα KO in skeletal muscle on IL-15 secretion and
IL-15 signal transduction, transgenic myoblast cell lines lacking IL-15Rα were generated via
stable transfection of C2C12 mouse myoblasts with plasmid vectors encoding a tGFP reporter
and one of two independent short hairpin RNAs (shRNA) against IL-15Rα. Wild type C2C12 cells
along with a stable cell line carrying the empty plasmid vector were used as controls for all
experiments. PCR targeting tGFP in isolated genomic DNA demonstrated stable plasmid
integration into the genome of all three transfected cell lines (Figure 3B). RT-PCR targeting
tGFP mRNA as well as visual detection of GFP fluorescence indicated plasmid expression
following genomic integration (Figure 3A, 3B). RT-PCR targeting IL-15Rα demonstrated a
selective knockout of IL-15Rα in both shRNA carrying cell lines, while IL-15Rα mRNA was

Figure 3. Characterization of stable cell lines.
(A) Visualization of tGFP reporter expression in IL-15Rα null and control myoblasts. (B) tGFP PCR
with DNA and cDNA templates from mature myotubes indicating stable plasmid integration and
expression in transgenic cell lines.
IL-15Rα-targeted RT-PCR indicating effective IL-15Rα
knockdown in mature myotubes stably carrying shRNAs. (C) No differences in doubling time were
observed between IL-15Rα null and control myoblasts. Data represent mean±SE for 4 independent
experiments.
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clearly detected in the empty vector and wild type controls (Figure 3B). Stable transfection did
not alter the proliferation rate of the transgenic myoblasts, as compared to wild type C 2C12
myoblasts of a similar passage number (Figure 3C).
3.2
Effects of chronic IL-15 treatment in the presence and absence of IL-15Rα:
In order to examine the effects of IL-15 treatment on mitochondrial density in vitro, as
well as to determine the effects of IL-15Rα loss on IL-15 response, WT and stable cells were
stimulated with IL-15 chronically during myotube formation and mitochondrial mass was
assessed via MitoTracker staining and mtDNA content was quantified using qPCR.
Quantification of mitotracker staining revealed a significant increase in MitoTracker staining per
nuclei in WT and EV cultures treated with 25 ng∙mL-1 IL-15, suggesting an increase in
mitochondrial mass. This effect was not observed in WT and EV treated with higher doses of IL15. No significant differences in MitoTracker staining were observed with IL-15 treatment in
either cell line lacking IL-15Rα, suggesting that this response requires IL-15Rα. Additionally,
cultures lacking IL-15Rα exhibited significantly less MitoTracker staining than WT and EV
controls under all treatment conditions (Figure 4A). No differences were observed in mtDNA

Figure 4. Effects of chronic IL-15 treatment on mitochondrial density.
(A) EV and WT cultures chronically treated with 25 ng∙mL-1 IL-15 exhibited a significant increase in
mitochondrial mass in comparison to EV and WT cultures which were untreated or treated with
higher doses of IL-15. IL-15 treatment had no significant effect on mitochondrial mass in cell lines
lacking IL-15Rα. Cultures lacking IL-15Rα exhibited significantly less mitochondrial mass in
comparison to WT and EV cultures under all conditions. (B) No differences in mtDNA content were
observed were observed in any cell line with IL-15 treatment. Cell lines lacking IL-15Rα displayed
significantly lower mtDNA content in comparison to WT and EV controls. Data represent mean±SE
for 4 independent experiments. Letters denote statistically identical means.
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content with IL-15 treatment in any cell line, however, shRNA carrying cell lines exhibited
significantly lower mtDNA counts in comparison to controls (Figure 4B)
In order to determine whether the alterations in mitochondrial mass observed with both
IL-15 treatment and IL-15Rα loss were a result of altered myogenesis or myotube morphology,
cultures were visually assessed with microscopy and both fusion index and myotube diameter
was analyzed. Visually, the 25 ng∙mL-1 IL-15 treatment appeared to result in a hypertrophic
myotube phenotype in EV and WT cultures, with myotubes in these cultures appearing to be of
greater mass than those in EV and WT cultures which were either untreated or treated with
higher doses of IL-15. Strikingly, cultures lacking IL-15Rα appeared under-fused with thin

Figure 5. Effects of chronic IL-15 treatment on mytube morphology.
(A) EV and WT cultures chronically treated with 25 ng∙mL-1 recombinant IL-15 visually appeared to
contain myotubes of greater mass than EV and WT cultures which were untreated or treated with
higher doses of IL-15. IL-15 treatment did not result in visually observable morphologic changes in
cultures lacking IL-15Rα. Visually, cultures lacking IL-15Rα appeared less fused with smaller
myotubes as compared to controls.
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myotube formations containing limited nuclei (Figure 5A).
Confirming these visual observations, measurement of myotube diameter revealed a
rightward shift in diameter distribution along with a significant increase in mean myotube
diameter in WT and EV cultures treated with IL-15 at the 25 ng∙mL-1 dose, suggesting that IL-15
treatment can result in an increase in myotube size. IL-15 treatment failed to yield a response
in terms of mytotube diameter at any dose in cultures lacking IL-15Rα, suggesting that IL-15Rα
is required for this response. Cultures lacking IL-15Rα displayed depressed mean myotube
diameters and leftward-shifted diameter distributions compared to control cultures under all
experimental conditions, suggesting that loss of IL-15Rα can negatively impact myotube size
(Figure 6A, 6B).
In terms of fusion index, which is expressed as the ratio of fused to total nuclei, IL-15
treatment failed to induce any significant change in fusion index at any dose in all four cell lines.
However, cultures lacking IL-15Rα were significantly less fused than controls under all
experimental conditions, suggesting that loss of IL-15Rα impairs myotube formation (Figure 6C).
No significant differences were observed in the total number of nuclei per field observed
between any set of experimental conditions, suggesting that the changes observed in both
myotube diameter and fusion index were not a result of altered culture nuclear content (Figure
6D).
Semi-quantitative RT-PCR targeting myosin heavy chain (MYH) was performed as a
molecular assessment of myogenic state. In EV and WT cultures, an increase in MYH mRNA
was detected with IL-15 treatment at the 25 ng∙mL-1 dose as compared to EV and WT cultures
which were either untreated or treated with higher doses of IL-15. IL-15 treatment failed to yield
a response in terms of MYH expression at any dose in cultures lacking IL-15Rα, once again
inferring a need for IL-15Rα in the ability to respond to IL-15. Consistent with our image
analysis, cultures lacking IL-15Rα displayed less detectable MYH mRNA as opposed to WT and
EV controls under all treatment conditions (Figure 7A).
In-situ ponceau staining was performed to quantify total cellular protein accretion;
ponceau staining was normalized to nuclear count, yielding a protein to nuclei ratio. In support
of the changes of MYH expression that were observed, significant increases in total culture
protein were observed in EV and WT lines treated with the 25 ng∙mL-1 dose of IL-15, with IL-15
treatment failing to yield a similar increase in IL-15Rα null cultures. Furthermore, cultures
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Figure 6. Quantification of myotube morphology following chronic IL-15 treatment.
(A) Chronic treatment of wild type and empty vector cultures with 25 ng∙mL-1 IL-15 during
myogenesis resulted in a rightward shift in myotube diameter distribution. Treatment of IL-15Rαnull cultures failed to yield a similar response at any dose. Diameter distributions generated
from cultures lacking IL-15Rα are shifted leftward in comparison to controls. (B) Chronic
treatment with 25 ng∙mL-1 IL-15 resulted in a significant increase in myotube diameter in EV and
WT cultures. IL-15 treatment had no significant effect on myotube diameter in cell lines lacking
IL-15Rα. Cultures lacking IL-15Rα exhibited significantly reduced myotube diameter in
comparison to WT and EV cultures under all conditions. (C) IL-15 did not affect the fusion index
of any treated cell line. Cultures lacking IL-15Rα exhibited significantly depressed fusion index
in comparison to WT and EV cultures under all conditions. (D) No differences in total nuclei per
field were observed between any experimental conditions. Data represent mean±SE for 3
independent experiments. Letters denote statistically identical means.
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Figure 7. Molecular characterization of myogensis following chronic IL-15 treatment.
(A) Chronic treatment with 25 ng∙mL-1 IL-15 resulted in a significant increase in MYH mRNA
expression EV and WT cultures. IL-15 treatment had no significant effect on MYH expression in cell
lines lacking IL-15Ra. Cultures lacking IL-15Rα exhibited significantly less MYH expression in
comparison to WT and EV cultures under all conditions. (B) Chronic treatment of WT and EV
cultures with 25 ng∙mL-1 IL-15 resulted in a visually apparent increase in ponceau staining. No
similar effect was observed in IL-15Ra deficient cultures at any dose. Cultures lacking IL-15Rα
displayed less prominent ponceau staining when compared to controls. (C) Chronic treatment with
25 ng∙mL-1 IL-15 resulted in a significant increase in the protein to nuclei ratio of EV and WT
cultures. IL-15 treatment had no significant effect on protein accretion in cell lines lacking IL-15Rα.
Cultures lacking IL-15Rα exhibited significantly lower protein to nuclei ratios in comparison to WT
and EV cultures under all conditions. (D) There are no significant differences in mitochondria to
protein ratio among any experimental conditions. Data represent mean±SE for 4 independent
experiments. Letters denote statistically identical means.
lacking IL-15Rα displayed lower protein content as opposed to WT and EV controls across all
treatment conditions (Figure 7B, 7C).
Taken as a whole, our analysis of myotube morphology and myogenic state suggests
that the changes observed in mitochondrial mass with IL-15 treatment and IL-15Rα loss were
confounded by altered myotube size and myogenic fusion. This is apparent when mitochondrial
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mass is normalized to total cellular protein, as no significant differences in mitochondria to
protein ratio are observed between any experimental conditions (Figure 7D).
3.3
Effects of acute IL-15 treatment on pro-oxidative gene expression:
Because of the confounding effects of chronic IL-15 treatment on myotube morphology
when examining the effects of IL-15 treatment on mitochondrial density, we alternatively
examined the effects of acute IL-15 treatment on pro-oxidative gene expression in mature WT
myotubes. Fully differentiated myotubes were stimulated with 25 ng∙mL-1 IL-15 for either 0, 1, 3,
or 12 hours and the transcriptional response of PGC-1α, PPARδ, and MYH was assessed via
semi-quantitative RT-PCR. A significant increase in PPARδ expression relative to vehicle was
observed after one hour of stimulation with IL-15, with this effect dissipating between 3 and 12
hours of stimulation (Figure 8A). Concurrently, a significant increase in PGC-1α expression
relative to vehicle was observed from 3 to 12 hours of IL-15 stimulation (Figure 8B). No
significant increases in MYH were observed at any time point (Figure 8C). These results

Figure 8. Effects of acute IL-15 treatment on pro-oxidative gene expression.
(A) Mature WT mytubes treated with recombinant IL-15 exhibited a significant increase in PPARδ
mRNA expression following one hour of treatment. (B) A significant increase in PGC-1α mRNA
expression was observed in cultures treated with IL-15 from 3 to 12 hours. (C) No significant
changes in MYH expression were observed with up to 12 hours of IL-15 treatment. (D) Time course
of gene expression changes observed with acute IL-15 treatment. Data represent mean±SE for 4
independent experiments. Letters denote statistically identical means.
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suggest that acute IL-15 treatment can induce pro-oxidative gene expression in a manner that
proceeds or avoids the changes in MYH expression observed with chronic IL-15 treatment
(Figure 8D).
3.4
Effects of IL-15Rα loss on IL-15 secretion In-Vitro:
In order to determine the effects of IL-15Rα loss on IL-15 secretion in-vitro, fully
differentiated myotubes lacking IL-15Rα were stimulated with lipopolysaccharide (LPS) in an
attempt to drive IL-15 secretion, and secreted IL-15 was measured in the cell culture
supernatant via ELISA and normalized to culture total cellular protein. EV and WT myotubes
exhibited a robust IL-15 secretory response to LPS stimulation at both 1 and 5 ug∙mL-1.
However, cultures lacking IL-15Rα failed to exhibit an increase in IL-15 secretion in response to
LPS and also displayed significantly lower levels of IL-15 in cell culture supernatants under
basal conditions as opposed to controls (Figure 9A). No differences were observed in nuclear
content between any of the experimental conditions (Figure 9C). However, consistent with our
data regarding the effects of IL-15Rα loss on myotube morphology and myogenic ability,
cultures lacking IL-15Rα displayed significantly less total cellular protein (Figure 9B). These data

Figure 9. Effects of IL-15Rα loss on IL-15 secretion in vitro.
(A) Treatment of mature WT and EV myotubes with LPS resulted in a significant increase in
secreted IL-15. LPS treatment failed to yield a secretory response in cell lines lacking IL-15Rα.
Cultures lacking IL-15Rα displayed significantly lower supernatant IL-15 levels under all conditions.
(B) Cultures lacking IL-15Rα significantly less total protein content than controls. LPS treatment did
not affect the total culture protein content of any cell line. (C) No differences were observed in
culture nuclei content under any experimental condition. Data represent mean±SE for 4 independent
experiments. Letters denote statistically identical means.
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suggest that IL-15Rα may be critical for IL-15 secretion in-vitro and also that LPS may be a
potent stimulator of IL-15 secretion in skeletal muscle.
3.5
Conditional knockout of IL-15Rα in mouse skeletal muscle:
In order to examine the effects of skeletal muscle IL-15Rα KO on IL-15 secretion in vivo,
site specific CRE recombination was used to generate a transgenic mouse model exhibiting
conditional loss of IL-15Rα in muscle. Mice were generated carrying LoxP sites flanking exons
2 and 3 of the IL-15Rα gene; the presence of CRE recombinase expression under the muscle
creatine kinase promoter (MCK) resulted in recombination at the LoxP sites, yielding effective
deletion of exons 2 and 3 specifically in muscle tissue (Figure 10A). Exons 2 and 3 of IL-15Rα
are essential for IL-15 binding, and its absence has been previously shown to result in a nonfunctional protein unable to interact with IL-15. PCR targeting the recombined IL-15Rα gene
confirmed selective recombination in skeletal and heart muscle tissue in mice expressing MCK
driven CRE. The 610 bp product denotes the presence of the LoxP floxed IL-15Rα allele, with
the 392 bp product only being possible after recombination (Figure 10B). RT-PCR using skeletal
muscle mRNA targeting the specific exons of IL-15Rα was performed to determine exonspecific expression of IL-15Rα following recombination. Primers were designed to produce
amplicons of IL-15Rα mRNA encoded by the following regions of the IL-15Rα gene: exons 1-4,
2-3, 4-8, 5-8, 6-8, 7-8, and 8-9. CRE- littermate controls produced all expected amplicons,
indicating the expression of all 9 exons of IL-15Rα. Amplicons spanning exons 1-4 and 2-3 were
absent in MCK CRE+ mice, with the remaining amplicons remaining present, indicating a loss of
expression of exons 1-3. An identical pattern of exonic expression was observed in muscle
tissue from the IL-15Rα global KO mouse (Figure 10C). RT-PCR targeting exons 2-3 of IL-15Rα
was performed in various tissues isolated from CRE+ mice, confirming that ablated mRNA
expression of these exons was a muscle specific effect (Figure 10D).
In an attempt to characterize IL-15Rα expression at the protein level, ELISA targeting IL15Rα was performed in lysates prepared from muscle, lung, kidney, and spleen as well as in
serum. No significant differences in IL-15Rα expression between MCK CRE+ and MCK CREmice were observed in any tissue type assayed, including muscle (Supplementary Figure 1A).
Based on the exonic expression profile observed

in the MCK CRE+ mouse, this may be

attributed to the presence of a truncated protein product, as exons 4-9 still appear to be
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Figure 10. Molecular characterization of muscle-specific IL-15Rα KO mice.
(A) Location of LoxP sites and primers. Forward primer 1 and reverse primer 1A target genomic
DNA and produce a 468 bp product when amplifying a wild type IL-15Rα allele, or 610 bp product
when LoxP sites are present. Forward primer 1 and reverse primer 1B target genomic DNA and
produce a 2000+ bp product which isn’t detectable by low-fidelity PCR when amplifying a nonrecombinated IL-15Rα allele, and a detectable 392 bp product when amplifying a recombined IL15Rα allele. Forward primer 2 and reverse primer 2 target IL-15Rα cDNA and produce a 280 bp
amplicon in the presence of IL-15Rα transcript containing exons 2 and 3. (B) PCR using forward
primer 1, reverse primer 1A, and reverse primer 1B produces a 610 bp product in MCK CRE- mice
indicating the homozygous presence of LoxP sites in all assayed tissues, and fails to produce the
392 bp product corresponding to a recombined IL-15Rα. Identical PCR in MCK CRE+ mice
produces a 610 bp product in all tissues along with a 392 bp product specifically in skeletal muscle
and heart, indicating recombination. (C) RT-PCR targeting the individual exons of IL-15Rα in cDNA
obtained from muscles of MCK CRE+ mice failed to produce amplicons spanning exons 1-4 and
exons 2-3. A similar pattern of expression was observed in the IL-15Rα global KO mouse.
Arrowheads represent predicted products. (D) RT-PCR targeting IL-15Rα in various tissues fails to
produce a product in skeletal muscle and cardiac tissue obtained from MCK CRE+ mice.
expressed on the transcriptional level. Accordingly, no significant differences were observed in
serum IL-15Rα (Supplementary Figure 1B).
3.6
Effects of IL-15Rα loss on IL-15 transcription and secretion in vivo:
In order to determine whether the loss of IL-15Rα specifically in skeletal muscle resulted
in alterations to IL-15 expression, RT-PCR was performed. MCK CRE+ mice lacking IL-15Rα
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conditionally in skeletal muscle displayed a significant increase in quadriceps IL-15 mRNA
expression, similar to what was previously reported with IL-15Rα loss in the global KO mouse
(Figure 11A). ELISA targeting IL-15 in serum was performed to determine whether this increase
in IL-15 mRNA expression resulted in changes in circulating IL-15. No significant differences in
serum IL-15 were observed between MCK CRE+ and littermate controls, suggesting that loss of
IL-15Rα specifically in skeletal muscle does not result in an increase in a substantial increase in
IL-15 secretion in vivo (Figure 11B).

Figure 11. Effects of muscle specific IL-15Rα loss on IL-15 expression in-vivo.
(A) RT-PCR targeting IL-15 in skeletal muscle reveals a greater abundance of IL-15 transcript in
muscles of MCK CRE+ mice in comparison to MCK CRE- controls. (B) ELISA targeting serum IL-15
revealed no significant differences in circulating IL-15 between the muscle specific IL-15Rα KO
mouse and littermate controls. (C) Identical ELISA in serum obtained from the IL-15Rα global KO
mouse shows significant increases in serum IL-15 in comparison to B6-129 controls. Data are
represented as mean±SE with letters denoting statistically identical means.
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Chapter 4.

Discussion:
Loss of IL-15Rα in the IL-15Rα global knock-out mouse has been shown to promote
remodeling of skeletal muscle towards an oxidative phenotype characterized by fatigue
resistance and a substantial increase in mitochondrial density, changes which would be deemed
positive in conditions of mitochondrial dysfunction. However, the mechanisms by which loss of
IL-15Rα in the global knockout results in pro-oxidative muscle changes was unclear, as IL-15
signaling in skeletal muscle has been virtually uncharacterized. It was previously suggested that
loss of IL-15Rα in the global KO mouse results in an increase in muscle IL-15 secretion, that
this increase in secreted IL-15 acts on skeletal muscle in an autocrine fashion to increase IL-15
signal transduction, and that this increase in IL-15 signaling directly results in pro-oxidative
changes. However, the ubiquitous absence of IL-15Rα in the IL-15Rα global KO mouse made it
difficult to determine whether the oxidative changes observed in skeletal muscle were a direct
result of IL-15Rα loss in muscle tissue alone, or whether changes in non-muscle tissues played
a contributing role. Additionally, the previously suggested mechanistic explanation presents
several paradoxes to the IL-15 signaling paradigms which have been established within the
immune system. Thus, our aim was to further explore the possible mechanisms responsible for
the pro-oxidative muscle changes observed in the global IL-15Rα KO mouse, and determine the
plausibility of the previously proposed mechanism. It was hypothesized that loss of IL-15Rα in
myogenic cultures and in-vivo in a muscle-specific fashion would increase IL-15 secretion. It
was also hypothesized that cultures lacking IL-15Rα would demonstrate a maintained ability to
respond to IL-15 in the presence of sufficiently elevated concentrations. Lastly, it was
hypothesized that myogenic cultures treated with IL-15 would exhibit evidence of increases in
mitochondrial density similar to what was observed in the skeletal muscle of the global IL-15Rα
KO mouse. Collectively, the data suggest that IL-15 may have the capacity to directly stimulate
pro-oxidative changes in skeletal muscle, and that the changes observed in the skeletal muscle
of the global IL-15Rα KO mouse may be attributed directly to increased response to IL-15.
However, contradicting what was observed in the global IL-15Rα KO mouse, the data suggest
that loss of IL-15Rα in skeletal muscle impairs IL-15 secretion as well as the ability to respond to
IL-15, suggesting that a confound in the global IL-15Rα KO mouse, such as immunodeficiency,
results in an altered ability to secrete and respond to IL-15.
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It was previously suggested that loss of IL-15Rα in skeletal muscle directly results in an
increase in IL-15 secretion. However, here we show that knockout of IL-15Rα in myogenic
cultures resulted in a significantly impaired ability to secrete IL-15, even in the presence of proinflammatory stress. In agreement with this observation, our conditional KO of IL-15Rα in mouse
skeletal muscle failed to yield an increase in circulating IL-15. These observations are
consistent with previous studies using other cell types which have suggested that IL-15Rα is
essential for IL-15 secretion,18,20,21,76 and suggest that IL-15Rα is equally as important in skeletal
muscle. Interestingly, we novelly showed an ability of cultured skeletal muscle to respond to
LPS stimulation with IL-15 secretion. This observation is constant with studies in lymphoid and
epithelial tissues which have shown a similar IL-15 secretory response to LPS.77–82 Due to the
role that IL-15 plays as an inflammatory mediator and immune cell chemo-attractant in other
tissues,53,83,84 it is not surprising that pro-inflammatory stimuli would result in IL-15 secretion
from muscle as well. However, it is interesting in respect to the potential function of IL-15 in
skeletal muscle, which is still ambiguous. Muscle IL-15 secretion is believed to be stimulated by
exercise85–89; our observations linking muscle IL-15 secretion to pro-inflammatory stimuli, taken
with the role that IL-15 has been shown to play in potentiating inflammation in conditions such
as arthritis,53 suggest that it may be possible that IL-15 is released by skeletal muscle following
exercise as an inflammatory response and acts to modulate post-exercise muscle inflammation.
It was previously suggested that IL-15 acts directly on skeletal muscle to drive prooxidative remodeling. Our attempt to explore the chronic effects of IL-15 signaling on
mitochondrial density in myogenic cultures was confounded by alterations in myotube
morphology. Chronic IL-15 treatment during differentiation appeared to enhance myogenesis,
resulting in a myotube phenotype characterized by increased myotube diameter, total protein
accretion, and transcriptional expression of MYH. This is consistent with other in-vitro studies
suggesting an anabolic role for IL-15 in skeletal muscle.90,91 Concurrently, loss of IL-15Rα had
an opposite effect, with cultures lacking IL-15Rα displaying a lower degree of myogenic fusion,
smaller myotubes diameters, decreased protein accumulation, and lower expression of MYH in
response to differentiative stimuli. As a whole, these data suggest a critical role for IL-15 and IL15Rα in the differentiative process in-vitro; however, the manner by which this occurs is unclear.
This may be a result of the ability of IL-15 to mediate signaling pathways which are commonly
considered inflammatory. There is prior evidence which implicate traditionally inflammatory
pathways such as p38 MAPK and NF-KB as being involved in the process of skeletal muscle
differentiation. Enhanced p52-RelB NF-KB heterodimer activity induced by overexpression of
28

IKKa, for example, has been shown to enhance myogenesis in a mechanism that appears to be
dependent on positive regulation of mitochondrial biogenesis.92 Interestingly, IL-15 treatment
has been shown to potently activate NF-KB pathways in various immune cells as well as bone
marrow progenitor populations.89,93 Thus, IL-15 mediated stimulation of NF-KB pathways which
influence mitochondrial biogenesis during differentiation is a potential explanation for the role
that IL-15 appears to play in influencing myogenesis in-vitro. However, it is important to note
that this effect of IL-15Rα loss on muscle differentiation only appears to occur in vitro, as
skeletal muscle in both the global and muscle specific IL-15Rα KO mouse models does not
appear to be developmentally impaired.16
Due to the effects of chronic IL -15 treatment in altering myotube morphology
confounding measures of mitochondrial density, we alternatively stimulated mature myotubes
with IL-15 acutely and assessed the response of the pro-oxidative genes PPARδ and PGC-1α,
to determine whether IL-15 can directly act on skeletal muscle in a pro-oxidative manner as
previously suggested. We observed induction of both PGC-1α and PPARδ following acute
treatment with IL-15. These data agree with previous in-vitro observations which have shown
that treatment of lymphocyte cultures with IL-15 results in potent PGC-1α activation and
increases in mitochondrial DNA content.94 Furthermore, these data also support in vivo studies
which have shown associative data linking pro-oxidative muscle remodeling to systemic
increases in IL-15,60,95 including those using the global IL-15Rα KO mouse,15,16 and suggest that
the muscle changes observed in these models are indeed a result of a direct effect of IL-15 on
skeletal muscle. However, the precise mechanism by which IL-15 results in these changes
remains unclear. This result was interesting with regards to what was observed with chronic IL15 treatment in that another PGC-1 isotype, PGC-1β, has been shown to be essential for
developmental mitochondrial biogenesis and effective myogenic differentiation.96 If IL-15 acts
on PGC-1β in similar manner, this may also offer another possible explanation as to why
altering IL-15 during differentiation appears to influence myogenesis.
Our data regarding the effects of chronic IL-15 treatment during myogenic differentiation
provided somewhat conflicting results in comparison to what we observed when treating mature
myotubes acutely with IL-15. Chronic IL-15 treatment during differentiation resulted in a
hypertrophic myotube phenotype characterized by increased expression of MYH, constituting
what appears to be an anabolic effect, while acute treatment of mature myotubes induced prooxidative gene expression, a seemingly opposing effect. One potential explanation for this
paradox, is the differential expression of pro-oxidative genes during the myogenic process. Both
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PPARδ and PGC-1α are virtually unexpressed in myogenic cultures for up to the first 3 days of
differentiation. However, both transcripts and their associated proteins are readily detectable in
mature myotubes.96 Thus, if IL-15 targets PGC-1α and PPARδ in mature skeletal muscle, the
fact that these proteins are not expressed during early differentiation may mean that IL-15
treatment during myogenesis results in an alternative gene activation program in their absence.
It was previously suggested that skeletal muscle could still respond to IL-15 in the
absence of IL-15Rα. To address this hypothesis, myogenic cultures lacking IL-15Rα were
chronically treated with IL-15 during differentiation to determine if they could undergo a similar
morphologic response as to what was observed in cultures expressing IL-15Rα. Cultures
lacking IL-15Rα failed to respond to IL-15 treatment in terms of myotube diameter, total protein
accretion, or MYH expression, even at significantly higher doses than those which yielded a
response in controls. This would suggest that loss of IL-15Rα disrupts IL-15 response in skeletal
muscle. These results are strongly consistent with what is observed in terms of IL-15 signaling
in the immune system, with the loss of IL-15Rα resulting in a significant decrease in the affinity
of IL-15 for its signaling receptors, effectively ablating IL-15 signaling.19,21,22
Taken as whole, these data provide further insight into the mechanisms responsible for
the pro-oxidative muscle changes observed in the global IL-15Rα mouse. Our data regarding
the effects of acute IL-15 treatment on pro-oxidative gene expression in myogenic cultures,
along with previous reports of oxidative muscle remodeling in transgenic mouse models of IL-15
overexpression,59 support the hypothesis that the changes observed in the skeletal muscle of
the global KO mouse are driven by an increase in IL-15 signaling at the muscle. However, in
contradiction, our data regarding the effects of IL-15Rα loss on IL-15 response in-vitro suggest
that IL-15Rα is essential in the ability of skeletal muscle to respond to IL-15. Furthermore, our
data regarding the effects of IL-15Rα loss on IL-15 secretion suggest that IL-15Rα is needed for
IL-15 secretion from skeletal muscle, contradicting the hypothesis that loss of IL-15Rα in the
global KO mouse results in an increase in IL-15 secretion from muscle. Thus, our findings
regarding secretion, as well as those previously reported in non-muscle tissues, make it difficult
to explain the increase in circulating IL-15 which is observed in the IL-15Rα global KO mouse
(Figure 12). It is interesting to note that the global model of IL-15Rα loss has been previously
characterized as having a moderatly compromised immune system, characterized by
lymphopenia and decreased NK cell counts.97 However, neither our in-vitro or in-vivo models of
muscle specific IL-15Rα loss account for a similar immune alteration. In our in-vitro experiments,
immune system interactions were eliminated, and due to the presence of IL-15Rα in the immune
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Figure 12. Results provide contradictory evidence regarding the
currently proposed mechanism of
pro-oxidative muscle remodeling
with loss of IL-15Rα.
(1) Loss of skeletal muscle IL-15Rα
both in-vivo and in-vitro failed to result
in increased IL-15 secretion, suggesting that loss of IL-15Rα alone is
not enough to drive an increase in IL15 secretion. (2) Loss of IL-15Rα ablated the ability of myogenic cultures
to respond to IL-15, suggesting that
IL-15Rα plays a critical role in muscle
IL-15 signal transduction. (3) Treatment of myogenic cultures with IL-15
resulted in induction of PGC-1α and
PPARδ, suggesting that IL-15 can act
directly on skeletal muscle to promote
pro-oxidative changes.
system in the muscle specific IL-15Rα KO, the immune system fails to exhibit similar
deficiencies as to what have been observed in the global KO, as total lymphocyte counts and
NK cell counts do not appear to be impacted (Supplementary Figure 2). Thus it is possible that
the immune deficiencies in the global IL-15Rα KO result in an enhanced ability to both secrete
and respond to IL-15 in an attempt to reconstitute immune homeostasis. This provides a likely
explanation regarding the contradictions which exist between our models of muscle specific IL15Rα loss and what is observed in the IL-15Rα global KO in terms of IL-15 secretion and
response. This represents an intriguing scenario, in that IL-15 is typically produced by peripheral
tissues in response to an immune challenge such as the presence of pathogen or damage
associated molecules to stimulate the maturation of NK cells and promote T-lymphocyte
survival.82,98–100 If it holds true that the IL-15 secretion is enhanced in the IL-15Rα global KO
mouse in response to immune deficiency, it would constitute a novel scenario in which IL-15
secretion is upregulated in the absence of an immune challenge or inflammatory stimulus, and
would furthermore suggest the existence of an uncharacterized feedback loop existing between
peripheral tissues and the immune system which acts to regulate IL-15 levels with respect to
basal immune status.
Collectively, these data provide additional perspective regarding the mechanisms
responsible for the oxidative changes observed in the IL-15Rα global KO mouse, as well as
novel insight regarding IL-15 signaling in skeletal muscle. These data show some evidence to
support the previous hypothesis that the mitochondrial changes observed in the IL-15Rα global
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KO mouse are directly driven by increased autocrine IL-15 signaling, and that IL-15 has the
capacity to act directly on skeletal muscle to promote pro-oxidative changes. However, these
data suggest that the increases in circulating IL-15 observed in the IL-15Rα global KO mouse
with loss of IL-15Rα may constitute a phenomenon driven by a confounding variable such as
immunodeficiency, and that loss of IL-15Rα in skeletal muscle alone does not result in an
enhanced ability to secrete IL-15 as previously proposed. Furthermore, these data suggest that
IL-15 signaling paradigms in skeletal muscle are similar to those which are observed in the
immune system, where IL-15Rα is essential in the ability to secrete and respond to IL-15. Due
to the positive mitochondrial changes observed in the IL-15Rα global KO mouse and other
models of systemically elevated IL-15, along with this new evidence of a direct pro-oxidative
action of IL-15 in skeletal muscle, the mechanisms by which IL-15 may act to influence oxidative
properties in skeletal muscle warrant further investigation, as IL-15 may prove to be a
therapeutically exploitable molecule in conditions of mitochondrial dysfunction.
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Chapter 5.

Experimental procedures:
5.1
Animals:
Mice with LoxP sites flanking exons 2 and 3 of the IL-15Rα gene were obtained as a
generous gift from Dr. Averil Ma, University of California San Francisco.

Transgenic mice

carrying the CRE recombinase gene under the control of the muscle creatine kinase promoter
were obtained from Jackson Laboratories (stock number 006475). Global IL-15RαKO mice
(stock no. 003723) and B6129 background control mice (stock no. 101045) were obtained from
Jackson Laboratories at 8 weeks of age and were used between 10 and 12 weeks of age to
maintain consistency with our previously published data16. Mice were housed in the animal
vivarium at West Virginia University at 22°C under a 12-hour light/12-hour dark cycle and
received food and water ab libitum. All animal experiments were approved by the Institutional
Animal Care and Use Committee at West Virginia University (ACUC#: 11-0804).
5.2
Generation of muscle-specific IL-15Rα KO mice:
A three-step breeding process was utilized to generate a skeletal and cardiac muscle
specific IL-15Rα KO mouse line. In step one of the breeding process, breeding pairs of mice
heterozygous for the LoxP-floxed IL-15Rα allele were used to generate IL-15Rα flox
homozygous mice at a frequency of approximately 25%. In step two, MCK-CRE hemizygous
mice were mated with IL-15Rα flox homozygous mice to obtain IL-15Rα flox heterozygous mice
carrying MCK CRE. In step three, IL-15Rα flox heterozygous mice carrying MCK CRE were
mated with IL-15Rα flox homozygous mice to obtain IL-15Rα flox homozygous mice carrying
MCK CRE, which represent the muscle-specific KO experimental mouse line, and IL-15Rα flox
homozygous mice lacking MCK CRE, which were used as littermate controls. Male and female
mice were used for experiments between the ages of 10 and 12 weeks.
For genotyping, genomic DNA was isolated from tail snips (2-4 mm) obtained from each
animal upon weaning at 21 days of age. The tissue was digested overnight at 55°C in 100 uL of
tail lysis buffer (Allele Biotechnology, San Diego, CA). The following morning, tissues were
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checked for sufficient digestion and then returned to the hot block for 15 minutes at 80°C to
denature the proteinase K.

PCR reactions were performed to determine the genotype of

animals using specific primers for the floxed IL-15Rα allele and MCK-CRE (Supplementary
Table 1). Amplification was performed using a solution consisting of 9.5 uL nuclease free water,
12.5 uL 2X Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville Scientific, Metuchen,
NJ), 0.5 uL forward primer, 0.5 uL reverse primer, and 2 uL of DNA template to make a 25 uL
total reaction volume. Following amplification, each reaction was visualized following gel
electrophoresis in 1.5% (w/v) agarose gels stained with ethidium bromide.
5.3
Analysis of IL-15Rα and IL-15 expression in transgenic mice:
Analysis of IL-15Rα at the genomic, transcriptional, and translational level was
performed in multiple tissues of MCK CRE+ and MCK CRE- mice to fully determine the effects
of recombination of exons 2 and 3 of the IL-15Rα gene. The following organs and skeletal
muscles were harvested and flash frozen in liquid nitrogen: quadriceps muscle, heart, liver,
spleen, kidney, lung, and brain. Genomic DNA was isolated from these tissues using a DNeasy
Blood and Tissue kit (Qiagen, Valencia, CA) and RNA was isolated using Trizol reagent (Life
Technologies, Grand Island, NY). PCR was performed using isolated DNA to verify the
genotyping results obtained from tail snips and also to determine that germline recombination
did not occur. RT-PCR was performed in all tissues using isolated RNA to examine tissuespecific expression of IL-15Rα. Quadriceps RNA was used to assess the effects of
recombination on exon-specific expression of IL-15Ra in skeletal muscle by performing RT-PCR
using primers designed to selectively target the individual exons of IL-15Rα. Semi-quantitative
RT-PCR was performed using RNA isolated from quadriceps muscle to assess IL-15
expression. ELISA targeting IL-15Rα in protein isolate was performed to assess the effects of
recombination on IL-15Rα protein expression.
5.4
Generation of IL-15Rα deficient stable myoblasts:
Low passage C2C12 murine myoblasts were used for all experiments and cultured using
standard aseptic technique (ATCC, Manassas, VA). Myoblasts were maintained under standard
mammalian culture conditions (37°C, 99% humidity, 5% CO2) in a growth media comprised of
high glucose Delbecco’s Modified Eagle Medium (DMEM)(Life Technologies) supplemented
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with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA) and antibiotics (Gibco,
Grand Island, NY). Cells were passed via trypsinization using 0.05% trypsin/EDTA in Hank’s
buffered saline solution (Life Technologies). For induction of myogenic differentiation, myoblasts
were incubated in a differentiation media comprised of high glucose DMEM containing 2% horse
serum (Atlanta Biologicals) and antibiotics.

Two commercially available plasmid constructs

encoding independent shRNAs against IL-15Rα and a green fluorescence protein reporter
(tGFP), along with an empty vector control (OriGene, Rockville, MD), were cloned using TOP-10
E-Coli (Life Technologies) and purified using the Qiagen Maxi-Prep system. Low-passage wild
type C2C12 myoblasts were then transiently transfected with purified plasmid constructs. For
transient transfection, cells were seeded in a 6-well plate at a density of 1∙105 cells per well in
growth media and incubated overnight. Cells were then transfected using a cationic polymer
transfection reagent (TurboFect, Thermo Scientific). 36 hours post-transfection, cells were
trypsinized and moved to 10 cm plates containing growth media supplemented with puromycin
(Sigma-Aldrich, St. Louis, MO) at a concentration of 5 ug∙mL-1. Cells were grown for 10 days in
puromycin, with media being replenished every 72 hours. tGFP-expressing colonies were then
transferred to 24-well plates using filter paper cloning discs and growth was continued under
selective pressure. Clonally-derived populations which displayed normal growth rates, high
tGFP expression, and no visible phenotypical abnormalities were further expanded for
experimentation. Final clonally-derived cell lines were screened for RNA expression of IL-15Rα
and tGFP using semi-quantitative RT-PCR. PCR for tGFP using genomic DNA template was
also performed to confirm genomic integration of plasmids.
5.5
Assessment of stable cell-line growth rates:
In order to determine the effects of IL-15Rα loss on myoblast proliferation, doubling time
of the generated stable cell lines was assessed. Stable cells as well as a wild type control were
seeded in triplicate in growth media at a density of 2∙104 cells per well (counted via
hemocytometer) in two identical 12-well plates. Three hours post-seeding, one of the duplicate
plates was fixed for 30 minutes at 37°C in 10% neutral buffered formalin (NBF). Following
fixation, cells were permeablized for 5 minutes using 0.1% Triton X-100 in PBS, and then
incubated for 10 minutes with PBS containing 25ul∙mL-1 NucBlue Hoechst 33342 (Life
Technologies) to stain nuclei. Nuclear staining intensity was then assessed using a fluorescent
plate reader (HT-1000, BioTek, Winooski, VT). For fluorescence quantification, a 29-point per
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well area scan was performed with excitation filters set at 360 nm and emission filters set at 460
nm. The second of the duplicate plates was fixed, stained, and quantified at 39 hours postseeding. Serial dilutions of a known quantitie of Hoechst-stained cells were used to generate a
7-point standard curve correlating Hoechst fluorescence to myoblast count. For standard curve
generation, cells were counted via hemocytometer and serial dilutions of a single cell
suspension were seeded in 12-well plates in triplicate. Cells were allowed to attach for 3 hours
and then fixed, stained, and quantified as described above. This standard curve was used to
estimate the myoblast count at both the three and 39 hour time points (Supplementary Figure
3). The difference between cell count at three and 39 hours was used to calculate the doubling
time for each stable cell line.
5.6
Chronic treatment of myogenic cultures with IL-15:
To determine the chronic effects of IL-15 treatment on myotube morphology and
mitochondrial density, as well as to determine the effects of IL-15Rα loss on IL-15 response, WT
and stable cells were stimulated with IL-15 during myotube formation. Twelve replicates of each
stable cell line as well as a wild type control were seeded in 12-well plates at a density of 1∙105
cells per well. Following 24 hours in growth media, cells were switched to differentiation media
to induce myotube formation. Each cell genotype was stimulated in triplicate with 0, 25, 100,
and 400 ng∙mL-1 recombinant IL-15 (R&D Systems, Minneapolis, MN) once daily during 4 days
of differentiation. Following four days of differentiation, cultures were either stained to assess
morphology and mitochondrial density, lysed for PCR analysis of myosin heavy chain (MYH)
expression, or incubated with ponceau to assess protein accretion.
5.7
Acute treatment of myogenic cultures with IL-15:
To determine the effects of acute IL-15 treatment on pro-oxidative gene expression,
mature WT myotubes were stimulated with IL-15 and the transcriptional response of prooxidative genes was assessed. Six replicates of WT myoblasts were seeded in growth media at
a density of 4∙105 in four identical 6-well plates. 24 hours post-seeding, confluent myoblasts
were exposed to differentiation media for four days, yielding mature myotubes. Triplicate wells
of each plate were then treated with either vehicle or 25 ng∙mL-1 recombinant IL-15. Plates were
then incubated for either 0, 1, 3, or 12 hours in the presence of IL-15. Following incubation, RNA
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was isolated and semi-quantitative RT-PCR was performed targeting PGC-1α , PPARδ, and
MYH. Gene expression of IL-15 and vehicle treated cultures was then compared at each time
point.
5.8
Assessment of mitochondrial density:
To determine the effects of chronic IL-15 treatment and IL-15Rα loss on mitochondrial
density, chronically IL-15 treated cultures were stained with MitoTracker Deep Red (Life
Technologies) to assess mitochondrial mass.

Cultures were incubated with differentiation

media containing 350 nM MitoTracker for 30 minutes.

Following MitoTracker incubation,

cultures were fixed for 30 minutes at 37°C in 10% NBF. Following fixation, cells were
permeablized for 5 minutes using 0.1% Tritin X-100 in PBS. Nuclei were then stained with
Hoechst and both Mitotracker and Hoechst fluorescence was quantified using a fluorescent
plate reader similar to what was previously described by Miyake et al.101 Excitation filters of 590
nm and emission filters of 645 nm were used to perform a 29-point per well area scan for
MitoTracker quantification. The same standard curve utilized for the proliferation assay was
used to estimate culture nuclei count from Hoechst fluorescence. MitoTracker RFU was then
normalized to nuclei count.
5.9
Mitochondrial DNA Content:
Total DNA (genomic and mitochondrial) was extracted from cell lysate using a DNeasy
Blood and Tissue kit (Qiagen) and quantified using a Nano-Drop spectrophotometer (Thermo
Scientific, Waltham, MA).

TaqMan primers (Life Technologies) targeting the mitochondrial

cytochrome-c oxidase subunit II (COXII) gene and nuclear 18S ribosomal RNA (18s) were used
to perform real-time qPCR. 20μl PCR reactions consisting of TaqMan 10X PCR Master Mix,
primers, and 5 ng of total DNA were prepared in a 96-well optical reaction plate and amplified
using the Applied Biosystems 7900HT Fast Real-Time PCR system. The cycle threshold (CT)
values were used to compare levels of COXII gene to 18S.
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5.10
Assessment of myotube morphology:
To determine the effects of chronic IL-15 treatment and IL-15Rα loss on myotube
morphology, myotube diameter and fusion index were assessed in chronically IL-15 treated
cultures. Cultures chronically treated with IL-15 were stained with MitoTracker and Hoechst as
described above. Following staining, 100x multi-channel fluorescent images were obtained
using a Zeiss AxioObserver inverted microscope equipped with a gas argon laser, appropriate
filter cubes, and a Zeiss AxioCam MRc5 digital camera (Zeiss, Thornwood, NY). Four random
images were obtained per well. For image analysis, any cell containing three or more nuclei was
considered to constitute a myotube. To assess myotube diameter, the diameter of every
myotube per field was manually measured at its widest width using the measure function of the
ImageJ ROI manager (National Institutes of Health, Bethesda, Maryland) and myotube diameter
distributions for each experimental condition were constructed. To assess fusion index, the
ImageJ cell counter plugin was used to count the number of nuclei contained in myotubes as
well as the total number of nuclei in each image. Fusion index was then expressed as the ratio
of nuclei contained in myotubes to the total number of nuclei. All image analysis was performed
blinded.
5.11
Measuring IL-15 secretion in vitro:
To determine the effects of IL-15Rα loss on IL-15 secretion, each stable cell line as well
as a wild type control were seeded in 12-well plates at a density of 1∙105 cells per well.
Following 24 hours in growth media, cells were switched to differentiation media for four days,
yielding mature myotubes. Each cell genotype was then stimulated in quadruplicate with 0, 1,
and 5 ug∙mL-1 lipopolysaccharide (Sigma-Adrich) in media comprised of high glucose DMEM
containing 1% culture grade bovine serum albumin (BSA)(Sigma-Aldrich). Following 24 hours of
LPS stimulation, supernatant was collected and immediately frozen at -80°C, and later assayed
for secreted IL-15 using ELISA. After supernatant collection, cells were then fixed and Hoechst
staining was used to estimate culture nuclei count as described for the proliferation assay.
Following Hoechst staining and quantification, total culture protein content was assessed using
ponceau staining. Total secreted IL-15 assayed via ELISA was then normalized to total culture
protein.
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5.12
IL-15 and IL-15Rα ELISA:
A custom IL-15-specific ELISA was developed using a commercially available ELISA
development kit (R&D Systems). For measurement of IL-15 in cell culture supernatant, anti-IL15 capture antibody was diluted in PBS at 4.0 ug∙mL-1, added to plates at 100 uL per well, and
incubated overnight at room temperature. Plates were then washed twice with PBST (0.05%
Tween20) followed by a wash single wash with PBS. Plates were blocked with 1% BSA in PBS
for one hour at room temperature.

Following washing, 100 uL of supernatant or standard

(recombinant IL-15 in 1% BSA DMEM) were added per well and incubated for one hour at room
temperature. Following sample incubation, plates were washed, and 100 uL biotinylated anti-IL15 detection antibody (400 ng∙mL-1 in PBS with 1% BSA, 2% normal goat serum) was added
per well. Plates were incubated for 2 hours at room temperature, washed, and incubated with
streptavidin HRP in 1% BSA PBS for 30 minutes at room temperature. Following washing, HRP
substrate solution and stop solution was added per manufactures recommendations. Optical
density of wells was determined via microplate reader (Epoch, BioTek) by measuring
absorbance at 450 nm with 570 nm wavelength correction. Four-parameter logistic regression
was used to generate a 7-point standard curve and sample IL-15 concentrations were
calculated. All samples and standards were assayed in duplicate.
For measurement of IL-15 in serum, the following modifications were made: plates were
blocked with 20% fetal calf serum (Atlanta Biologicals) in PBS, serum samples were diluted 1:10
in 1% BSA PBS, and standards were diluted in 1% BSA PBS.
For the assessment of tissue IL-15Rα expression, tissue samples were powdered in
liquid nitrogen, solubilized in PBS containing 0.1% NP-40, and spun at 20,000∙g to pellet
insoluble debris. Homogenate protein content was assayed via the DC assay and 100 ug of
total protein was assayed once again via custom ELISA.
For ELISA targeting IL-15Rα, the R&D DuoSet system was once again used to develop
a custom assay. Anti-IL-15Rα capture antibody was diluted in PBS at 8.0 ug∙mL-1, added to
plates at 100 uL per well, and incubated overnight at room temperature. Plates were then
washed and blocked with 20% FCS in PBS for one hour at room temperature.

Following

washing, 100 uL of sample (100 ug protein isolate in 1% BSA PBS) or standard (recombinant
IL-15Rα in 1% BSA PBS) were added per well and incubated for one hour at room temperature.
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Following sample incubation, plates were washed, and 100 uL biotinylated anti-IL-15Rα
detection antibody (200 ng∙mL-1 in PBS with 1% BSA, 2% normal goat serum) was added per
well and incubated for 2 hours at room temperature. Colormetric detection was then performed
as described for ELISA targeting IL-15.
5.13
Assessment of total culture protein content:
Total culture protein was determined using a method modified from Hayner et al.102
Fixed and permeablized cultures were incubated with 0.5% Ponceau S (Acros Organics, Fair
Lawn, NJ) in 5% acetic acid for 30 minutes. Following staining, plates were rinsed twice in 5%
acetic acid and once in distilled water. Bound ponceau was then solubilized in 2.0 M NaOH for
10 minutes on a rocker plate. 50 uL of solubilized ponceau was then removed from the culture
plate and placed into a 96-well microtitre plate for spectrophotometry. Optical density was then
determined by measuring absorbance at 550 nm. A 6-point standard curve was generated
correlating ponceau absorbance to protein content assessed using the DC assay, and was used
to estimate total protein based on 550 absorbance. For standard curve generation, serial
dilutions of myoblasts were seeded in duplicate in identical 12-well plates. After allowing one
hour for adherence, cells from one plate were solubilized in RIPA buffer (Sigma-Aldrich) and
assayed via the DC assay (Bio-Rad, Hercules, CA), while cells from the other identical plate
were fixed and assayed via the ponceau staining method described above. 550 absorbance
from the ponceau assay was then plotted against DC assay protein content to yield a standard
curve (Supplementary Figure 4).
5.14
RNA Isolation and RT-PCR:
For both animal tissues and cultured cells, total RNA was isolated using Trizol reagent
(Life Technologies) per manufactures recommendations. RNA quantity and quality were
assessed using a Nano-Drop 2000 spectrophotometer (Thermo Scientific); the 260/280 ratio for
all samples used was between 1.8 and 2.0. Two ug of total RNA was reverse transcribed to
make cDNA using a high-capacity reverse transcription kit according to manufacturer's
instructions (Life Technologies). Amplification was performed using a solution consisting of 9.5
uL nuclease free water, 12.5 uL 2X Taq-Pro Red Complete 1.5 mM MgCl2 master mix (Denville
Scientific), 0.5 uL forward primer, 0.5 uL reverse primer, and 2 uL of cDNA to make a 25 uL total
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reaction volume. Following amplification, each reaction was visualized following gel
electrophoresis in 1.5% (w/v) agarose gels stained with ethidium bromide.
For semi-quantitative experiments, primer pairs for target sequences were co-amplified
with primer pairs for 18S (Ambion, Austin, TX). The number of PCR cycles was determined in
preliminary experiments to ensure analyses were done in the linear range of amplification. PCR
band intensity was quantified using the ImageJ gel analysis plugin. Signals for the gene of
interest were normalized to the bands for 18S that were amplified in the same reaction. Primer
sequences and amplification conditions for all RT-PCR can be found in Supplementary Table 1.
5.15
Statistical analysis:
All data were quantified and analyzed using the GraphPad Prism 5.0 statistical software
package (GraphPad Software Incorporated, La Jolla, CA). All experiments were performed in
triplicate or quadruplicate in 3-4 independent experiments (n=3-4), data are presented as mean
± SE, and the null hypothesis was rejected when P<0.05.

One or two-way ANOVA with

bonferroni post-hoc testing was used where appropriate based on the number of independent
variables.
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Chapter 7.

Supplementary Data:

Supplementary Figure 1. Effects of muscle specific IL-15Rα recombination on IL-15Rα
protein expression.
(A) ELISA revealed no significant differences in IL-15Rα protein expression between tissues
obtained from the muscle-specific IL-15Rα KO mouse and those obtained from MCK CRE- littermate
controls. (B) No differences in circulating IL-15Rα were observed between MCK CRE+ and MCK
CRE- negative mice. Data are represented as mean±SE.

Supplementary Figure 2. Effects of muscle specific IL-15Rα loss on lymphocyte counts.
(A) Flow cytometric detection of immunolabeled spleenocytes revealed no significant differences
between MCK CRE+ mice and littermate controls in terms of total lymphocyte count (CD3+/NK1.1-)
(B) No significant differences were observed in total number of NK cells (CD3-/NK1.1+). (C) No
significant differences were observed in number of NK-lymphocytes (CD3+/NK1.1+). (D) No
significant differences were observed in number of total NK cells (NK1.1+). Data are represented as
mean±SE.
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Supplementary Figure 3. Standard curve generation for fluorescent assessment of
culture nuclear content.
(A) Representative images of serially-diluted Hoechst-stained cultures used for standard curve
generation. (B) Standard curve used for quantification of nuclear content. There was a strong
positive correlation between number of cells seeded and Hoechst fluorescence. Increases in cell
number resulted in a ratiometrically similar increase in Hoechst fluorescence. Data are represented
as mean±SD.

52

Supplementary Figure 4. Standard curve generation for assessment of total cellular
protein.
(A) Representative images of serially-diluted myoblast cultures used for standard curve generation.
(B) The top of panel B shows the resultant ponceau staining of serially diluted myoblast cultures.
The bottom of panel B shows solubilized ponceau obtained from the staining of serially diluted
myoblasts. (C) Standard curve used for quantification of total cellular protein. There was a strong
positive correlation between DC assay protein concentration and ponceau absorbance obtained
from identical myoblast serial dilutions. Increases in culture protein resulted in a ratiometrically
similar increase in ponceau absorbance. Data are represented as mean±SD.
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Supplementary Table 1. Primers and PCR Conditions.
TARGET:

IL-15Rα exons1-4
IL-15Rα exons 2-3

SEQUENCE:

F: 5'-GAATCGTCCGCCCAGAACTT
R: 5'-TGTGAGGTCACCTTTGGTGT
F: 5'-ATCCGGGGGCTAAAGCAAAA
R: 5'-TTCTTGACCCGGATGTCAGC

IL-15Rα exons 4-8

F: 5'- GACCCCTCCCTAGCTCACTA
R: 5'- CACCAACCAAGAGGACCGAT

IL-15Rα exons 5-8

F: 5'- AGGCTGACACCATCCCAAAC
R: 5'- CACCAACCAAGAGGACCGAT

IL-15Rα exons 6-8

F: 5'- CAGTTCCAAAATGACGAAAGTGGC
R: 5'- CCAACCAAGAGGACCGATGT

IL-15Rα exons 7-8

F: 5'- CGAGTACCCTGTCATCGGTT
R: 5'- ATCACAACCCCTGCACCAAC
F: 5'- ACATCGGTCCTCTTGGTTGG
R: 5'- GGGCTTTCTCCTGTGTCCAG

IL-15Rα exons 8-9

IL-15
Turbo-GFP
PGC-1a
PPar-d
B-Actin
MYH
IL-15Ra Flox
CRE Deletion
MCK CRE
MCK CRE Int Con

F: 5'- TCTTCATGGTCCTTGCTGGT
R: 5'- GGCCTCTGTTTTAGGGAGACC
F: 5'- GATGGGCTACGGCTTCTACC
R: 5'- CCTCGTAGCGGTAGCTGAAG
F: 5'- TGGTTGCCTGCATGAGTGTG
R: 5'- AGGGCAATCCGTCTTCATCC
F: 5'- GTGCAGCGGTGTGGGTAT
R: 5'- CCATGACTGACCCCCACTTG
F: 5'- ACGTACATGGCTGGGGTGTT
R: 5'- ACAGTTTCACCTGCCCTGAGT
F: 5'- AGAAGGAGGAGGCAACTTCTG
R: 5'- ACATACTCATTGCCGACCTTG
F: 5'- GGCAGTCAGCAAAGAAAGTTGG
R: 5'- TTCCATCCATTCAGTGCGGC
F: 5'- GGCAGTCAGCAAAGAAAGTTGG
R: 5'- CGATAAAGGTGGGCATCTACAGC
F: 5'- GTGAAACAGCATTGCTGTCACTT
R: 5'- TAAGTCTGAACCCGGTCTGC
F: 5'- GTCAGTCGAGTGCACAGTTT
R: 5'- CAAATGTTGCTTGTCTGGTG

ACCESSION:

NM_133836.2
NM_001271497.1
NM_008358.2
NM_001271499.1
NM_001271500.1
NM_001271501.1
NM_008358.2
NM_133836.2
NM_001271497.1
NM_001271499.1
NM_001271500.1
NM_008358.2
NM_133836.2
NM_001271497.1
NM_001271498.1
NM_008358.2
NM_133836.2
NM_001271497.1
NM_001271498.1
NM_001271499.1
NM_001271500.1
NM_001271501.1
NM_001271498.1

PRODUCT (bp):

520
404
280
280
280
280
370
370
370
271
172
196
196
196
267
74
74
74
74
74
74
74
103

NM_008358.2
NM_133836.2
NM_001271497.1
NM_001271498.1
NM_001271499.1
NM_001271500.1
NM_001271501.1
NM_001254747.1
NM_008357.2
-

265
265
265
265
265
265
265
394
394
155

NM_008904.2

396

NM_011145.3

164

NC_000071.6

109

NM_001039545.2
NM_030679.1
NM_010855.3
NC_000068.7
NC_000068.7

650
650
650
WT: 468
Flox: 610
392

-

450

NC_000080.6

200

TM =Melting Temperature

TM:

94°C
30s
94°C
30s

TA:

55°C
30s
56°C
30s

TE:

72°C
45s
72°C
45s

CYCLES:

40
40

94°C
30s

55°C
30s

72°C
45s

40

94°C
30s

55°C
30s

72°C
45s

40

94°C
30s

55°C
30s

72°C
45s

40

94°C
30s
94°C
30s

55°C
30s
55°C
30s

72°C
45s
72°C
45s

40

94°C
30s
94°C
30s
94°C
30s
94°C
30s
94°C
30s
94°C
30s

55°C
30s
55°C
30s
55°C
30s
55°C
30s
55°C
30s
55°C
30s

72°C
45s
72°C
45s
72°C
45s
72°C
45s
72°C
45s
72°C
45s

29

94°C
60s
94°C
60s
94°C
30s
94°C
30s

61°C
60s
61°C
60s
64°C
30s
64°C
30s

72°C
120s
72°C
120s
72°C
30s
72°C
30s

34

T A=Annealing Temperature

40

35
35
34
35
30

34
35
35

T E=Extension Temperature

54

